Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation

R. E. Steg; A. Kessinger; Z. K. Wszolek

doi:10.1038/sj.bmt.1701732

Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation

R. E. Steg, A. Kessinger, Z. K. Wszolek

Neurology

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.

Original language	English (US)
Pages (from-to)	959-962
Number of pages	4
Journal	Bone Marrow Transplantation
Volume	23
Issue number	9
DOIs	https://doi.org/10.1038/sj.bmt.1701732
State	Published - 1999

Keywords

Bone marrow transplantation
Cortical blindness and seizures
FK506 neurotoxicity

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1701732

Cite this

@article{3d47feae94694464b69d512fc3f3cafb,

title = "Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation",

abstract = "A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.",

keywords = "Bone marrow transplantation, Cortical blindness and seizures, FK506 neurotoxicity",

author = "Steg, {R. E.} and A. Kessinger and Wszolek, {Z. K.}",

year = "1999",

doi = "10.1038/sj.bmt.1701732",

language = "English (US)",

volume = "23",

pages = "959--962",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation

AU - Steg, R. E.

AU - Kessinger, A.

AU - Wszolek, Z. K.

PY - 1999

Y1 - 1999

N2 - A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.

AB - A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.

KW - Bone marrow transplantation

KW - Cortical blindness and seizures

KW - FK506 neurotoxicity

UR - http://www.scopus.com/inward/record.url?scp=0032910099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032910099&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701732

DO - 10.1038/sj.bmt.1701732

M3 - Article

C2 - 10338054

AN - SCOPUS:0032910099

SN - 0268-3369

VL - 23

SP - 959

EP - 962

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 9

ER -

Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this